NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
| Image |  |
|---|---|
| Description | scientific article published on 2 July 2013 |
| Author/s |
author: Stephan Stilgenbauer Michael Hallek Daniel Mertens Konstanze Döhner Thorsten Zenz Hartmut Döhner |
| Publication date | July 2, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |